Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation

American Journal of Transplantation

Volumn 4, Issue 12, 2004, Pages 2045-2051

  Glander, Petra ^b   Hambach, Pia ^a   Braun, Kay Patrick ^a   Fritsche, Lutz ^a   Giessing, Markus ^a   Mai, Ingnid ^a   Einecke, Gunilla ^a   Waiser, Johannes ^a   Neumayer, Hans Hellmut ^a   Budde, Klemens ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b NONE

Author keywords

IMP dehydrogenase; Kidney transplantation; Mycophenolate mofetil; Pharmacodynamics

Indexed keywords

INOSINATE DEHYDROGENASE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DOSE CALCULATION; DRUG DETERMINATION; DRUG EFFECT; ENZYME ACTIVITY; EXPERIENCE; FEMALE; GRAFT REJECTION; HUMAN; KIDNEY TRANSPLANTATION; LOGISTIC REGRESSION ANALYSIS; MALE; MONONUCLEAR CELL; OUTCOMES RESEARCH; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC;

AREA UNDER CURVE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; KIDNEY TRANSPLANTATION; MIDDLE AGED; MYCOPHENOLIC ACID; ODDS RATIO; PREOPERATIVE CARE; REOPERATION; ROC CURVE; TIME FACTORS; TREATMENT OUTCOME;

EID: 10044283192     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2004.00617.x     Document Type: Article

References (26)

1. Andrews PA. Renal transplantation. BMJ 2002; 324: 530-534.
2. Sollinger HW for the U.S. Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225-232.
3. Keown PA for the Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029-1037.
4. Pichelmayr R for the European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321-1325.
5. Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf 2001; 24: 645-663.
6. Squifflet JP for the European Tacrolimus-MMF Renal Study Group. Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients. Transplantation 2001; 72: 63-69.
7. Mourad M, Malaise J, Chaib Eddour D et al. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. Clin Chem 2001; 47: 1241-1248.
8. Pelletier RP, Akin B, Henry ML et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 2003; 17: 200-205.
9. Knoll A, MacDonald I, Khan A, van Walraven C. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003; 14: 2381-2386.
10. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47: 85-118.
11. Langman LJ, LeGatt DF, Halloren PF, Yatscoff RW. Pharmaco-dynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients. Transplantation 1996; 62: 666-672.
12. Glander P, Hambach P, Braun KP et al. Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients. Int J Clin Pharmacol Ther 2003; 41: 470-476.
13. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55:713-723.
14. Glander P, Braun KP, Hambach P et al. Non-radioactive determination of inosine 5′-monophosphate dehydrogenase (IMPDH) in peripheral mononuclear cells. Clin Biochem 2001; 34: 543-549.
15. Hale MD, Nicholls AJ, Bullingham RE et al. The pharmacokinetic- pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 1998; 64: 672-683.
16. van Gelder T, Hilbrands LB, Vanrenterghem Y et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999; 68: 261-266.
17. Weber LT, Shipkova M, Armstrong VW et al. The pharmacokinetic- pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German study group on mycophenolate mofetil therapy. J Am Soc Nephrol 2002; 13: 759-768.
18. Shaw LM, Kaplan B, DeNofrio D, Korecka M, Brayman KL. Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation. Ther Drug Monit 2000; 22: 14-19.
19. Shaw LM, Korecka M, Venkataramanan R, Goldberg L, Bloom R, Brayman KL. Mycophenolic acid pharmcodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant 2003; 3: 534-542.
20. Holt DW, Armstrong VW, Griesmacher A, Morris RG, Napoli KL, Shaw LM. International Federation of Clinical Chemistry/International Association of Therapeutic Drug Monitoring and Clinical Toxicology working group on immunosuppressive drug monitoring. Ther Drug Monit 2002; 24: 59-67.
21. Budde K, Glander P, Bauer S et al. Pharmacodynamic monitoring of mycophenolate mofetil. Clin Chem Lab Med 2000; 38: 1213-1216.
22. Bennett WM. Immunosuppression with mycophenolic acid: one size does not fit all. J Am Soc Nephrol 2003; 14: 2414-2416.
23. Maes BD, Dalle I, Geboes K et al. Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea. Transplantation 2003; 75: 665-672.
24. Meier-Kriesche HU, Steffen BJ, Hochberg AM et al. Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection. Am J Transplant 2003; 3: 68-73.
25. Meier-Kriesche HU, Steffen BJ, Hochberg AM et al. Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation 2003; 75: 1341-1346.
26. Schnitzler MA, Hardinger KL, Brennan DC. Graft survival and cost following gastrointestinal complications in renal transplant recipients treated with mycophenolate mofetil (abstract). Nephrol Dial Transplant 2003; 18(Supplement 4): 789-790.